PharmaCyte Biotech financials
$0.4190−0.21%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jul 31 | Q4 '26 Apr 30 | Q3 '26 Jan 31 | Q2 '26 Oct 31 | Q1 '26 Jul 31 | Q4 '25 Apr 30 | Q3 '25 Jan 31 | Q2 '25 Oct 31 | Q1 '25 Jul 31 | Q4 '24 Apr 30 | Q3 '24 Jan 31 | Q2 '24 Oct 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$1.0M | -$5.9M | -$2.1M | -$1.4M | -$848.3K | -$1.0M | -$4.3M | -$1.1M | -$1.3M | -$3.2M | -$1.9M | -$1.4M |
| Net income | -$5.8M | -$20.2M | -$1.6M | -$8.4M | -$8.4M | $10.8M | -$18.3M | -$3.0M | $15.0M | -$2.5M | -$5.6M | -$2.3M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.54 | $-1.89 | $-0.17 | $-1.24 | $-1.23 | $1.75 | $-2.41 | $-0.39 | $1.90 | $-0.30 | $-0.65 | $-0.26 |
| EBITDA | -$1.0M | -$4.3M | -$2.1M | -$1.4M | -$848.3K | -$1.0M | -$4.3M | -$1.1M | -$1.3M | -$1.2M | -$1.9M | -$1.4M |
| Operating cash flow | -$780.9K | -$1.4M | -$786.8K | -$979.5K | -$2.0M | -$1.0M | -$509.9K | -$1.1M | -$373.3K | -$333.0K | -$177.1K | -$2.0M |
| Free cash flow | -$780.9K | -$1.4M | -$786.8K | -$979.5K | -$2.0M | -$1.0M | -$509.9K | -$1.1M | -$373.3K | -$333.0K | -$177.1K | -$2.0M |
| Diluted shares | 10.7M | 10.7M | 9.3M | 6.8M | 6.8M | 6.2M | 7.6M | 7.6M | 7.9M | 8.4M | 8.6M | 8.8M |
Balance sheet
| Period end | Jul 31 | Apr 30 | Jan 31 | Oct 31 | Jul 31 | Apr 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $17.7M | $18.6M | $20.2M | $15.4M | $13.2M | $15.2M |
| Short-term investments | $12.8M | $18.5M | $372.3K | $201.2K | $261.9K | $366.3K |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $36.7M | $46.8M | $55.9M | $56.0M | $45.1M | $55.2M |
| Total liabilities | $6.9M | $11.8M | $16.5M | $19.4M | $1.5M | $3.3M |
| Shareholders' equity | $27.5M | $33.3M | $38.1M | $35.2M | $43.6M | $51.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology